MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (โAvenueโ or the...
- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024...
MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (โAvenueโ or the...
MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (โAvenueโ or the...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.